Pep IQ
← Pep IQ
P21 (P021) is a tetrapeptide mimetic built from the most active region (residues 148–151) of ciliary neurotrophic factor (CNTF), developed by the Iqbal group at the New York State Institute for Basic Research. A γ-aminoadamantane group at the C-terminus gives it metabolic stability and blood–brain-barrier penetration, letting it work when given by mouth. In the 3×Tg-AD Alzheimer's mouse model, chronic oral P021 raised BDNF, restored hippocampal neurogenesis and synaptic density, and reduced tau hyperphosphorylation with a partial drop in amyloid-β. Benefit has also been reported in Down syndrome (Ts65Dn) and CDKL5-deficiency models, and improved cognition in normal adult mice and rats.
Two threads run in parallel. P21 mimics CNTF and partially inhibits leukaemia inhibitory factor (LIF) signalling through STAT3 — lifting a brake on dentate-gyrus neurogenesis. Separately it increases BDNF expression, which activates TrkB → PI3K → AKT and drives inhibitory phosphorylation of GSK-3β at Ser9. Because GSK-3β is a major tau kinase, suppressing it lowers tau hyperphosphorylation and modestly reduces amyloid processing. The net described effect is a shift from neurodegeneration toward neurogenesis and synaptic repair.
None. Every efficacy and safety finding for P21 comes from cell-culture and rodent studies. There are no published human clinical trials, no human pharmacokinetics, and no human safety data of any kind. The compound has not entered clinical development at the time of writing.
Not approved as a medicine by the MHRA, FDA or any equivalent body. Not a controlled substance and not scheduled in the UK — sold only through research-chemical vendors. WADA does not list P21. Its sole legitimate context is laboratory research.
The rodent disease-modifying data is unusually consistent for an experimental peptide, and oral activity is a genuine point of interest. But the gap to humans is total: no trials, no human dosing, no human safety. Community injectable protocols are extrapolated from oral animal studies and should be read as untested. P21 is a promising research molecule — not a validated intervention. And unlike its neuro cousins (Semax, Selank, Pinealon), it has almost no grassroots user base — the dosing tables in circulation are vendor-authored, not community-derived.
Ciliary neurotrophic factor is one of the brain's most potent neurotrophic cytokines — central to neuronal survival, differentiation and adult hippocampal neurogenesis. As a drug, though, the full protein is a poor candidate: large, unstable, and antigenic. The Iqbal group set out to find the smallest stretch of CNTF that retained its biology, mapping antibody-binding sites to isolate the active region and whittling it down to a short core sequence. P21 is the optimised result — a tetrapeptide that reproduces much of CNTF's activity in a compact, chemically stable form.
To survive in the body and reach the brain, the peptide was capped with an N-terminal acetyl group and a γ-aminoadamantane-1-carboxylic acid at the C-terminus. That adamantane cage is the same chemical trick seen in the Dihexa/Adamax class: it confers stability and lipophilicity for blood–brain-barrier crossing, and is why P21 is active orally where almost no peptide is. A near-identical analogue, P22, moved the N-terminal group and lost its effect — a reminder of how finely tuned the structure is.
A note on the name. “p21” also refers to the cyclin-dependent kinase inhibitor p21Cip1/Waf1, an unrelated cell-cycle protein involved in senescence and cancer biology. The two share nothing but the label, and vendor pages and search results frequently conflate them. This entry is about the CNTF-derived neurotrophic peptide only.
P21's described effects are “disease-modifying” in the models that have studied it — meaning it appears to shift the underlying biology rather than simply mask symptoms. The mechanism reads as two reinforcing loops, both downstream of mimicking CNTF.
The most-cited work gave P21 in the diet of 3×Tg-AD mice from three months of age — well before overt pathology — and continued for roughly eighteen months, reporting preserved cognition and reduced tau and amyloid burden at moderate-to-severe disease stages. Whether any of this translates to humans is entirely unknown: no clinical step has been taken.